SOHO 2022 | The utility of MRD for predicting treatment outcomes in patients with CLL
William Wierda
• 28 Sep 2022
In this video, William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the use of measurable residual disease (MRD) for predicting treatment outcomes in chronic lymphocytic leukemia (CLL), drawing focus on the prognostic value of MRD in patients treated with a BCL-2 inhibitor. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
